Table of Contents PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Disease overview • Understanding the disease • Economic burden • Types of lung cancer • Diagnosis • Staging of SCLC • Staging of NSCLC • Key buying criteria PART 06: Pipeline analysis PART 07: Market landscape • Global lung cancer therapeutics market • Five forces analysis PART 08: Market segmentation by disease type • NSCLC • Global NSCLC market overview • SCLC • Global SCLC market overview PART 09: Market segmentation by type of molecule • Small molecules • Biologics PART 10: Geographical segmentation • Lung cancer therapeutics market in Americas • Lung cancer therapeutics market in EMEA • Lung cancer therapeutics market in APAC PART 11: Market drivers • Growing demand for targeted therapies • Presence of blockbuster drugs coupled with longer patent exclusivities • Advancements in identification of molecular biomarkers increasing patient pool • Paradigm shifts toward the adoption of checkpoint inhibitors PART 12: Impact of drivers PART 13: Market challenges • Growing popularity of alternative therapeutics • High costs leading to low adoption rate • Adverse effects of drugs PART 14: Impact of drivers and challenges PART 15: Market trends • Emergence of nanomedicine platform for the treatment of lung cancer • Advent of miRNA therapeutics in the treatment of lung cancer • Growing strategic alliances for late-stage pipeline • Growing approvals in lung cancer therapeutics market PART 16: Vendor landscape • Competitive scenario PART 17: Key vendor analysis • F. Hoffmann-La Roche • Eli Lilly • AstraZeneca • Pfizer • Celgene • Other prominent vendors PART 18: Appendix • List of abbreviations PART 19: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Key customer segments of global lung cancer therapeutics market Exhibit 03: Snapshot of lung cancer Exhibit 04: Types of lung cancer Exhibit 05: Main diagnostic procedures to determine presence of lung cancer Exhibit 06: Staging of SCLC Exhibit 07: Illustration of stages of NSCLC disease Exhibit 08: Key buying criteria for lung cancer therapeutics Exhibit 09: Factors affecting adoption rates of lung cancer therapeutics Exhibit 10: Pipeline analysis of key vendors in global lung cancer therapeutics market Exhibit 11: Percentage share of drug candidates by stage of development Exhibit 12: Phase III pipeline portfolio: Global lung cancer therapeutics market Exhibit 13: Phase II pipeline portfolio: Global lung cancer therapeutics market Exhibit 14: Phase I pipeline portfolio: Global lung cancer therapeutics market Exhibit 15: Global lung cancer therapeutics market snapshot Exhibit 16: Analysis of global lung cancer therapeutics market Exhibit 17: Global lung cancer therapeutics market size and forecast 2015-2020 ($ billions) Exhibit 18: Opportunity analysis of global lung cancer therapeutics market Exhibit 19: Opportunity analysis in developed and emerging markets Exhibit 20: Five forces analysis Exhibit 21: Segmentation of global lung cancer therapeutics market by disease type 2015 and 2020 Exhibit 22: Life cycle analysis of key segments in global lung cancer therapeutics market 2015 Exhibit 23: Types of NSCLC Exhibit 24: Potential drugs/drug candidates in global NSCLC therapeutics market Exhibit 25: Key drivers impacting market growth in NSCLC Exhibit 26: Global NSCLC therapeutics market size and forecast 2015-2020 ($ billions) Exhibit 27: Opportunity analysis in global NSCLC market Exhibit 28: Key points in SCLC Exhibit 29: Key drivers impacting market growth in SCLC Exhibit 30: Global SCLC therapeutics market size and forecast 2015-2020 ($ billions) Exhibit 31: Opportunity analysis in global SCLC therapeutics market Exhibit 32: Segmentation of global lung cancer therapeutics market by type of molecule 2015 Exhibit 33: Global lung cancer therapeutics market by geographical segmentation 2015-2020 Exhibit 34: Segmentation of global lung therapeutics market based on geography 2015 and 2020 Exhibit 35: Lung cancer therapeutics market revenue by geography 2015-2020 ($ billions) Exhibit 36: Lung cancer therapeutics market in Americas 2015-2020 ($ billions) Exhibit 37: Key trends across various countries in Americas Exhibit 38: Lung cancer therapeutics market size and forecast in EMEA 2015-2020 ($ billions) Exhibit 39: Drivers in lung cancer therapeutics market in EMEA Exhibit 40: Key strategic initiatives in various countries in EMEA Exhibit 41: Lung cancer therapeutics market size and forecast in APAC 2015-2020 ($ billions) Exhibit 42: Key drivers and challenges in APAC Exhibit 43: YoY growth rate of Avastin 2015 Exhibit 44: Performance of blockbuster drugs in 2015 Exhibit 45: Patent exclusivities of few blockbuster drugs Exhibit 46: Recent launches of checkpoint inhibitors Exhibit 47: Impact of drivers Exhibit 48: Alternative therapies for lung cancer therapeutics Exhibit 49: Costs of few lung cancer drugs ($) Exhibit 50: Force field analysis of drivers and challenges in global lung cancer therapeutics market Exhibit 51: Impact of drivers and challenges Exhibit 52: Trend analysis in global lung cancer therapeutics market Exhibit 53: Key factors driving adoption of nanomedicine Exhibit 54: Factors driving adoption of miRNA therapeutics Exhibit 55: Key deals in global lung cancer therapeutics market Exhibit 56: Recent approvals of lung cancer therapeutics Exhibit 57: Competitive analysis in global lung cancer therapeutics market Exhibit 58: Market penetration of various lung cancer therapeutics manufacturers in global (2015) Exhibit 59: Regional analysis of vendors in global lung cancer therapeutics market Exhibit 60: Vendors ranking in global lung cancer therapeutics market Exhibit 61: F. Hoffmann-La Roche: Key highlights Exhibit 62: F. Hoffmann-La Roche: Strength assessment Exhibit 63: F. Hoffmann-La Roche: Strategy assessment Exhibit 64: F. Hoffmann-La Roche: Opportunity assessment Exhibit 65: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions) Exhibit 66: F. Hoffmann-La Roche: Geographic segmentation of Avastin by revenue 2015 Exhibit 67: F. Hoffmann-La Roche: YoY growth and revenue generated from net product sales of Tarceva 2013-2015 ($ billions) Exhibit 68: F. Hoffmann-La Roche: Geographic segmentation of Tarceva by revenue 2015 Exhibit 69: Eli Lilly: Key highlights Exhibit 70: Eli Lilly: Strength assessment Exhibit 71: Eli Lilly: Strategy assessment Exhibit 72: Eli Lilly: Opportunity assessment Exhibit 73: Eli Lilly: YoY revenue and growth rate of Alimta 2013-2015 ($ billions) Exhibit 74: Eli Lilly: Geographic segmentation by revenue of Alimta 2015 Exhibit 75: Eli Lilly: YoY and growth rate of Cyramza 2014-2015 ($ millions) Exhibit 76: Eli Lilly: Geographic segmentation by revenue of Cyramza 2015 Exhibit 77: AstraZeneca: Key highlights Exhibit 78: AstraZeneca: Strength assessment Exhibit 79: AstraZeneca: Strategy assessment Exhibit 80: AstraZeneca: Opportunity assessment Exhibit 81: AstraZeneca: YoY revenue and growth rate of Iressa 2013-2015 ($ billions) Exhibit 82: AstraZeneca: Geographic segmentation of Iressa 2013-2015 (% share) Exhibit 83: Pfizer: Key highlights Exhibit 84: Pfizer: Strength assessment Exhibit 85: Pfizer: Strategy assessment Exhibit 86: Pfizer: Opportunity assessment Exhibit 87: Pfizer: YoY revenue and growth rate of Xalkori 2013-2015 ($ millions) Exhibit 88: Celgene: Key highlights Exhibit 89: Celgene: Strength assessment Exhibit 90: Celgene: Strategy assessment Exhibit 91: Celgene: Opportunity assessment Exhibit 92: Celgene: YoY revenue and growth rate of Abraxane 2013-2015 ($ millions)

F. Hofmann-La Roche, Eli Lilly, AstraZeneca, Pfizer, Celgene, Abbvie, Aetna, Agennix, Allergan, Amgen, ARIAD Pharmaceuticals, Astellas Pharma, Betta Pharmaceuticals, BeyondSpring Pharmaceuticals, BioNumerik Pharmaceuticals, Boehringer Ingelheim, Boston Biomedical, Bristol-Myers Squibb, Celldex, CTI BioPharma, Eisai, GlaxoSmithKline, GTx, Helsinn, Hutchison Medipharma, Ionis Pharmaceuticals, Kadmon Corporation, MabVax, Merck, Novartis, NovaRx Corporation, OncoGeneX, Ono Pharmaceutical, OSE Immunotherapeutics, OSI Pharmaceuticals, Peregrine, PharmaMar, Pierre Fabre, Qiagen, Recombio, Samsung Bioepis, Sanofi, SFJ Pharmaceuticals, Spectrum Pharmaceuticals, Sumitomo Dainippon Pharma, Synta, Takeda Pharmaceuticals, Teva Pharmaceutical, Xcovery.